14
Total investments
6
Early stage
4
Mid stage
0
Late stage
9y
Years active
Portfolio
13 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Jul 2024
We are creating a new category of medicines with the application of spatial biology and AI.
Board Observer
Jun 2024
Vilya is a cutting-edge computational biotechnology company, co-founded a team of scientists from from the Institute of Protein Design (IPD) led by David Baker, Ph.D. and by ARCH Venture Partners.
At Vilya, we are creating a novel class of medicines to precisely target disease biology. Our platform is built on ground-breaking research in advanced computational approaches and taps into uncharted chemical space within cyclic peptides to design new molecular structures not found in nature.
We aim to boldly leverage cutting edge computing to change how we design new medicines, and to ultimately cure diseases.
Who will love working with us?
We are a group of machine learning scientists, computational chemists, medicinal chemists, biologists and scientific enthusiasts that are driven to design and create life-altering medicines that will make a big impact on the world. Learn more about our job openings and join us!
join@vilyatx.com
Board Member
May 2023
Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease.
We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines.
Archon Biosciences is based in Seattle and supported by a team of forward-thinking investors led by Madrona Ventures. Our AbC platform was invented with the science and technology recognized by the 2024 Nobel Prize in Chemistry at the Baker Lab in the Institute for Protein Design (IPD).
If you are interested in partnering or see yourself as part of our mission, please contact us at contact@archon.bio.
Board Member
Oct 2021
Terray is a biotechnology company with the technology, data, and mindset to radically change the way we discover and develop small molecule therapeutics. We explore molecules and targets broadly and deeply with a sophisticated integration of ultra-high throughput experimentation, generative AI, biology, medicinal chemistry, automation, and nanotechnology. Everything the company does is grounded in an iterative approach, producing massive amounts of precise, purpose-built data that gets increasingly valuable with each cycle of design and experimentation. The company’s platform uniquely blends experimentation and computation to improve the cost, speed, and success rate of small molecule drug discovery and development.
Board Observer
Feb 2019
Ovation is a leading provider of genomic data for the life sciences industry. We are dedicated to supporting the advancement of precision medicine and offer access to a wide range of high-quality, consented genomic data linked to diverse, longitudinal phenotypic data at scale. Our data allows researchers to identify and validate biomarkers, discover new targets and understand resistance mechanisms in various populations. Our cloud-based LIMS system allows clinical labs to easily adopt innovative molecular tests, while also transforming samples into valuable research-grade data across various disease areas. Learn more at www.ovation.io.
Board Observer
Jan 2019
Knock®, a RealPage company®, offers an integrated suite of front office technology that provides multifamily owners and operators with the levers they need to more profitably acquire and retain high-value, long-term residents. Knock CRM empowers leasing teams with tools to accelerate successful leasing and renewal outcomes, provides marketers the data to optimize spend, and ensures executives have the business intelligence and insights needed to outperform their competitors.
Board Observer
May 2018
Welcome to Shyft!
Shyft is your one-stop mobile labor optimization solution for hourly workers.
FEATURED IN:
| Bloomberg | Fox Business News | Wall Street Journal | The Seattle Times
| The Toronto Star | The Boston Globe | TIME | Money |
Shyft is a mobile-first solution for schedule distribution, schedule changes, and team messaging. We’re the front end mobile product for your workforce management solution.
For more information contact us at Hello@myshyft.com
Board Observer
Jan 2018
At Unearth, we’ve built mobile software – OnePlace – that connects the office, trailer, and field on a simple yet powerful map.
Contractors lose precious hours in the search for jobsite information. Photos get dumped in folders, hundreds of plan sheets are stuffed in lists, and you’re left trying to communicate these files over a maze of text, email, and clunky apps.
With OnePlace, you can visualize the entirety of your project, track progress in real time, and collaborate with crews on the jobsite, on any device.
Empty your folders and geolocate everything against a comprehensive map: photos, drawings, documents, drone surveys, GIS, and more. Seeing everything in context makes it easy to find the information you need, so you can get the job done fast.
From site planning to field operations, OnePlace has cut the time required by inspections, QA/QC, reporting, data tracking, and issue resolution by over 50% for major owners and contractors.
See how OnePlace can save hours in your week with a 30-day free trial.
Board Observer
Dec 2017
Taste, transparency and convenience shouldn’t be mutually exclusive. This has been our founding belief since we started in 2015, and it continues to be the force that drives us.
It’s why we partner with ethical farms, fisheries and producers around the world. Source delicious, high-quality and more sustainable food. Share the stories of the producers we carry. And make our products easy to access, no matter where you live in the country.
This is the recipe for a great meal at home — food that’s better for you, better for the earth, better for the animals and better for the hardworking farmers, fishermen and producers behind it all. So come join the food transparency movement and taste the difference, because the difference tastes better.
Board Observer
Dec 2017
In 2015, we launched our company with a mission to power the delivery of everything. Since then, we completely reinvented the way vehicles get energy, saving more than eight million miles and four million pounds of CO2 emissions. Booster is energy delivered, integrated logistics, and society’s solution for decarbonizing the last mile.
Board Observer
Dec 2017
Amperity is the customer data platform that helps brands build the unified first-party customer data foundation they need to grow revenue, reduce costs, save time, and stay compliant.
Our unparalleled solution creates accurate, reliable profiles by stitching together every type of rich customer data across disparate sources using patented AI and Machine Learning methods.
Teams including Marketing, IT, and Analytics can easily use these profiles to drive business value – boosting acquisition and retention, discovering historical and predictive insights, creating high-value segments, fueling tools that deliver personalized customer experiences, meeting privacy and compliance standards, and adapting to future evolutions of the tech stack.
Amperity’s unique combination of complete profiles, streamlined access, advanced insights, and surprising speed creates the customer data confidence brands need to power meaningful experiences and accelerate growth.
More than 400 brands worldwide rely on Amperity to turn data into business value, including Alaska Airlines, DICK’S Sporting Goods, Endeavour Drinks, Planet Fitness, Seattle Sounders FC, Under Armour and Wyndham Hotels & Resorts.
Board Observer
Dec 2017
AnsweriQ is an intelligent automation solution for customer service. Using the power of AI and IPA, AnsweriQ's suite of products help customer service leaders automate information and process-based cases.
For information cases, AnsweriQ provides Zero Contact Resolution without an agent's intervention. This is achieved through self-service AI and automated responses.
For process cases, AnsweriQ enables single-click intelligent automation for repetitive and mundane customer service processes. These processes typically require agents to traverse through multiple systems ranging from order look up, cancellation, invoicing, refunds, etc.
AnsweriQ’s products seamlessly integrate with popular CXM systems like Zendesk, Salesforce, ServiceCloud, ServiceNow, Microsoft Dynamics, etc. AnsweriQ’s intelligent automation can deliver unto a 25% reduction in case volume. AnsweriQ’s process automation delivers up to 90% savings in average handle time and close to 100% reduction in error rates. AnsweriQ also assists agents with AI-based recommended responses that improve CSAT, NPS, and agent morale.
Experience · 16 entries
All (16)
Investments (14)
Board (14)
2024
Board Member
Jul 2024
We are creating a new category of medicines with the application of spatial biology and AI.
Board Observer
Jun 2024
Vilya is a cutting-edge computational biotechnology company, co-founded a team of scientists from from the Institute of Protein Design (IPD) led by David Baker, Ph.D. and by ARCH Venture Partners.
At Vilya, we are creating a novel class of medicines to precisely target disease biology. Our platform is built on ground-breaking research in advanced computational approaches and taps into uncharted chemical space within cyclic peptides to design new molecular structures not found in nature.
We aim to boldly leverage cutting edge computing to change how we design new medicines, and to ultimately cure diseases.
Who will love working with us?
We are a group of machine learning scientists, computational chemists, medicinal chemists, biologists and scientific enthusiasts that are driven to design and create life-altering medicines that will make a big impact on the world. Learn more about our job openings and join us!
join@vilyatx.com
2023
Board Member
May 2023
Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease.
We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines.
Archon Biosciences is based in Seattle and supported by a team of forward-thinking investors led by Madrona Ventures. Our AbC platform was invented with the science and technology recognized by the 2024 Nobel Prize in Chemistry at the Baker Lab in the Institute for Protein Design (IPD).
If you are interested in partnering or see yourself as part of our mission, please contact us at contact@archon.bio.
2021
Board Member
Oct 2021
Terray is a biotechnology company with the technology, data, and mindset to radically change the way we discover and develop small molecule therapeutics. We explore molecules and targets broadly and deeply with a sophisticated integration of ultra-high throughput experimentation, generative AI, biology, medicinal chemistry, automation, and nanotechnology. Everything the company does is grounded in an iterative approach, producing massive amounts of precise, purpose-built data that gets increasingly valuable with each cycle of design and experimentation. The company’s platform uniquely blends experimentation and computation to improve the cost, speed, and success rate of small molecule drug discovery and development.
Show all 16 entries ↓
Investment activity
2017–2024 · 14 investments
Recent (last 2 years)Earlier
